IMR Press / FBL / Volume 7 / Issue 5 / DOI: 10.2741/johnston

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Overcoming cardiac allograft vasculopathy (CAV) by inducing tolerance
Show Less
1 The Transplantation Biology Research Center and the Division of Cardiac Surgery, Department of Surgery, Massachusetts General Hospital and the Laboratory of Immunogenetics and Transplantation, Brigham and Women’s Hospital, Boston, Massachusetts
2 The Transplantation Biology Research Center, Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA
3 The Laboratory of Immunogenetics and Transplantation, Renal Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
4 Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA
Front. Biosci. (Landmark Ed) 2002, 7(5), 116–128;
Published: 1 May 2002

There is compelling evidence that MHC-driven immune processes play a dominant role in the development of cardiac allograft vasculopathy. Thus, it makes intuitive sense that tolerance, which eliminates donor alloreactivity, should protect against CAV. However, in the experimental literature, there are examples of CAV occurring in recipients rendered tolerant by either peripheral or central induction protocols. Why does transplant arteriopathy occur in recipients that have achieved a robust state of tolerance or in the animals devoid of T or B cell immunity? There may be immunological blindspots that persist even after a state of tolerance is achieved. These blindspots could contribute to the pathogenesis of chronic rejection (CR).

Cardiac Allograft Vasculopathy
Graft Rejection
Heart Transplantation
Transplantation Tolerance Review
Back to top